NNIT A/S: 10/2020 Financial report for the first six months of 2020


Company announcement 10/2020: Financial report for the first six months of 2020

Revenue decrease of 4.7% and an operating profit margin before special items of 6.0% in the first six months of 2020

Performance highlights for the second quarter of 2020:

  • Revenue decreased by 5.7% in Q2 2020 compared to Q2 2019 due to a 26% decline from the Novo Nordisk Group and a 10% decline within the enterprise segment
  • Revenue from life sciences Denmark and life sciences international increased by 22% and 18% respectively whilst the public segment contributed with a strong growth of 12%. Revenue within the finance segment declined by 3.4% whilst revenue from the enterprise segment declined by 10% mainly due to the phasing out of the Pandora outsourcing contract
  • By the end of Q2 2020, the share of NNIT’s revenue from clients outside the Novo Nordisk Group increased to 75% from 68% in Q2 2019
  • COVID-19 was seen to mainly impact NNIT’s project business in April and May whilst growth returned to more normal levels in June
  • Gross profit margin was 13% in Q2 2020 (13% in Q2 2019). The margin was negatively impacted by the declining business with the Novo Nordisk Group and Pandora and as a result of COVID-19. The negative impact was partly offset by the cost restructuring program. An asset review of the useful lifetime of certain assets had a positive margin impact of 1.0pp for the quarter (+0.4pp for the full year)
  • Operating profit margin before special items decreased to 5.4% in Q2 2020 from 5.9% in Q2 2019. Operating profit margin after special items for the quarter was 3.6%
  • Net profit was DKK 14m in Q2 2020 compared to DKK 34m in Q2 2019 due to restructuring costs of DKK 13m as well as a negative impact from financials
  • Order backlog for 2020 at the beginning of Q3 2020 was DKK 2.507m, a decrease of 8.1% compared to the same time last year, negatively impacted by a large decline of 29% from the Novo Nordisk Group
  • Outlook for 2020:

The guidance for 2020 is maintained:

  • Revenue growth of -4% to -8% in constant currencies
  • Operating profit margin before special items of 6-8% in constant currencies
  • Level of investments (CAPEX) is 5-7% of total revenue

Due to the continued uncertainty regarding the COVID-19 impact on the 2020 activity level there is an increased likelihood that revenue growth and operating profit margin will end in the lower end of the guidance intervals

  • Due to the underlying cash flow generation and the strong financial position of NNIT, the Board of Directors has decided to pay an interim dividend for 2020 of DKK 2.00 per share corresponding to DKK 49.4 million

Per Kogut, CEO at NNIT comments: “I’m satisfied with the financial performance of the quarter which is in line with our expectations despite COVID-19 and declining revenue from the Novo Nordisk Group and Pandora. This is achieved by solid revenue growth within our life science business growing 20%, as well as execution of the cost restructuring program.”

Conference call details
NNIT will host a teleconference August 13, 2020 at 10:30 CET about the financial report for the first six months of 2020. Please visit the NNIT webpage at to access the teleconference, which can be found under ‘Investors – Events & presentations. Presentation material will be available on the website approximately one hour prior to the start of the presentation.

Conference call details

Participant telephone numbers:
Denmark:                                   +45 45 7815 0110
United Kingdom:                       +44 333 300 9269
Sweden:                                      +46 850 558 357
United States:                            +1 646 722 4956

Financial Calendar 2020
August 17, 2020                        Interim dividend ex-dividend date
August 18, 2020                        Interim dividend record day
August 19, 2020                        Interim dividend payment date
October 29, 2020                      Interim report for the first nine months of 2020

Forward-looking statements
This announcement contains forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events which may prove incorrect.
Please also refer to the overview of risk factors in the ‘risk management’ section on page 29-31 in the Annual Report 2019.

Contacts for further information
Investor relations:                              Media relations:                
Jens Binger                                          Tina Joanne Hindsbo
Head of Investor Relations          NNIT Communications                 
Tel: +45 3079 9222                          Tel: +45 3077 9578                

About NNIT
NNIT A/S is one of Denmark’s leading IT service providers and consultancies. NNIT A/S offers a wide range of IT services and solutions to its customers, primarily in the life sciences sector in Denmark and internationally and to customers in the public, enterprise and finance sectors in Denmark. As of June 30, 2020, NNIT A/S had 3,078 employees. NNIT has approximately 400 clients of which around 150 are located outside Denmark. Some 25% are international life sciences clients. For more information please visit


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation19.9.2020 16:25:00 CESTPress release

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in patients with lung or liver metastases, which are observed in 41% of postmenopausal women with HR+ aBC, and considered more aggressive and challenging to treat1-3 Data add to growing body of evidence for Piqray, the first and only treatment specifically approved for aBC with a PIK3CA mutation Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvestrant, compared to fulvestrant alone, in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients with tumors harboring a PIK3CA mutation. Piqray is the only trea

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma19.9.2020 16:20:00 CESTPress release

Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 Data show positive durable responses and progression-free survival benefit for patients treated with Tafinlar + Mekinist in the comparator arm of the COMBI-i clinical trial despite the study not meeting the primary endpoint for the investigational triplet therapy Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agents Basel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone1. The efficacy data achieved in the trial’s control arm among patients treated with Tafinlar + Mekinist represent the long

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 202019.9.2020 16:20:00 CESTPress release

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapyFinal overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours expressed PD-L1 and who received Tecentriq plus nab-paclitaxelResults from the Phase III IMpassion131 study, evaluating Tecentriq in combination with paclitaxel for the treatment of people with metastatic TNBC and whose tumours expressed PD-L1, did not meet its primary endpoint of progression-free survival Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical

Galapagos increases share capital through subscription right exercises18.9.2020 22:01:00 CESTPress release

Mechelen, Belgium; 18 September 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 86,280 new ordinary shares on 18 September 2020, for a total capital increase (including issuance premium) of €2,403,087. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,435,739.72, the total number of securities conferring voting rights amounts to 65,340,842, which is also the tota


Sveriges Riksbank Bid procedure details Government Bonds, 2020-09-25 Maturity dateLoanISIN codeCouponVolume, SEK million2029-11-121061 SE00112819220.75 %1,000 +/- 2502032-06-01 1056 SE00045172902.25 %1,000 +/- 250 Settlement date 2020-09-29 Bids have to be entered by 10.00 on SEP 25, 2020 Highest permitted bid volume: 1 000 million in issue SGB 1061 and 1 000 SEK million in issue SGB 1056 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON SEP 25, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at


Sveriges Riksbank CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS Bid procedure on 22 September 2020, Municipalities and Regions Bonds: Floating-Rate Notes (FRN) issued in SEK by Municipalities or Regions with maturity in 2025. The following issuers are accepted for delivery: Göteborgs KommunJönköpings KommunMalmö KommunNorrköpings Kommun Skåne Läns LandstingStockholms KommunSundsvalls KommunTäby KommunUppsala KommunVästerås KommunÖrebro KommunÖstersunds Kommun Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 11 September 2020. Bids: Bids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to Bid date: Tuesday 22 September 2020 Bid time: 1000-1100 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 750 +/- 750 million Highest permitted bid vol